|
|
 Previous Article | Table of Contents | Next Article 
Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus
anticoagulant
F Lellouche, M Martinuzzo, P Said, J Maclouf and LO Carreras
U348 INSERM, Hopital Lariboisiere, Paris, France.
The mechanism involved in the association between antiphospholipid
antibodies and thrombosis or fetal loss remains unclear. We assessed the
biosynthesis of thromboxane A2 and prostacyclin in 31 samples from 25
patients with lupus anticoagulant and in 32 controls. The urinary excretion
of the major thromboxane metabolite of platelet origin (11-
dehydrothromboxane B2) was very significantly increased (P less than .0003)
in the patients. In contrast, the urinary metabolite reflecting the
vascular production of prostacyclin (2,3-dinor-6-keto-prostaglandin F1
alpha) was much less increased (P less than .02). We found no correlation
between the levels of anticardiolipin antibodies and the urinary excretion
of 11-dehydro-thromboxane B2. Six patients with elevated urinary
11-dehydrothromboxane B2 were treated with low-dose aspirin (20 mg/d during
7 days). In these patients, there was a close relationship between the
extent of inhibition of the thromboxane urinary metabolite (72%) and serum
thromboxane B2 (79%). In contrast, the urinary excretion of
2,3-dinor-6-ketoprostaglandin F1 alpha was nearly unchanged (13%
reduction). In addition, the F(ab')2 fragments isolated from six patients
presenting increased urinary 11-dehydro- thromboxane B2 enhanced the
generation of thromboxane B2 (P = .04) and the release of 14C serotonin (P
= .009) by normal washed platelets, as compared with F(ab')2 from controls.
In summary, our study shows that in patients with lupus anticoagulant,
platelet activation may occur without a compensatory increment in the
vascular biosynthesis of prostacyclin. This observation may be crucial to
cause or reflect an increased risk for thrombosis. In addition, our results
may suggest a rationale for antiplatelet agents for the prophylaxis of
thrombosis in many patients with the antiphospholipid syndrome.
Volume 78,
Issue 11,
pp. 2894-2899,
12/01/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
I. Avalos, C. P. Chung, A. Oeser, G. L. Milne, H. Borntrager, J. D. Morrow, P. Raggi, J. Solus, and C. M. Stein
Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus
Lupus,
December 1, 2007;
16(12):
981 - 986.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. A. Ozturk, I. C. Haznedaroglu, M. Turgut, and H. Goker
Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2004;
10(2):
89 - 126.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Kohyama, X. Liu, H. J. Kim, T. Kobayashi, R. F. Ertl, F.-Q. Wen, H. Takizawa, and S. I. Rennard
Prostacyclin analogs inhibit fibroblast migration
Am J Physiol Lung Cell Mol Physiol,
August 1, 2002;
283(2):
L428 - L432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Rand
Molecular Pathogenesis of the Antiphospholipid Syndrome
Circ. Res.,
January 11, 2002;
90(1):
29 - 37.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P R J Ames, C Tommasino, J Alves, J D Morrow, L Iannaccone, G Fossati, S Caruso, F Caccavo, and V Brancaccio
Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study
Lupus,
November 1, 2000;
9(9):
688 - 695.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R Hilker, A Thiel, C Geisen, and J Rudolf
Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome
Lupus,
May 1, 2000;
9(4):
311 - 316.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Roubey
Review : Mechanisms of autoantibody-mediated thrombosis
Lupus,
January 1, 1998;
7(2_suppl):
S114 - S119.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. R.J. Ames
Medical Perspective Antiphospholipid Antibodies, Thrombosis and Atherosclerosis in Systemic Lupus Erythematosus: a Unifying 'Membrane Stress Syndrome' Hypothesis
Lupus,
October 1, 1994;
3(5):
371 - 377.
[PDF]
|
|
|
|
|
|
|
S. S. Pierangeli and E. N. Harris
Antiphospholipid Antibodies in an in vivo Thrombosis Model in Mice
Lupus,
August 1, 1994;
3(4):
247 - 251.
[PDF]
|
|
|
|
|
|
|
L. O. Carreras and J. Maclouf
Antiphospholipid Antibodies Eicosanoids
Lupus,
August 1, 1994;
3(4):
271 - 273.
[PDF]
|
|
|
|
|
